Biotechnology - Japan

Filter

Current filters:

Japan

Popular Filters

MedImmune and Shionogi sign license agreement for Shionogi's preclinical biologics in acute coronary syndrome

MedImmune and Shionogi sign license agreement for Shionogi's preclinical biologics in acute coronary syndrome

09-10-2014

MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

BiotechnologyCardio-vascularCrestorJapanLicensingMedImmuneShionogi

Daiichi Sankyo to buy Ambit Biosciences for up to $410 million

Daiichi Sankyo to buy Ambit Biosciences for up to $410 million

29-09-2014

Daiichi Sankyo and Ambit Biosciences have entered into a definitive merger agreement under which Daiichi…

Ambit BiosciencesBiotechnologyDaiichi SankyoJapanMergers & AcquisitionsOncologyquizartinib

Gilead files for Japanese approval of ledipasvir/sofosbuvir for hepatitis C

24-09-2014

Gilead Sciences has submitted a New Drug Application to Japan’s Pharmaceutical and Medical Devices…

Anti-viralsBiotechnologyGilead SciencesJapanledipasvirRegulationsofosbuvir

iBio collaborates with Kanematsu Chemicals to target Japanese market

iBio collaborates with Kanematsu Chemicals to target Japanese market

14-08-2014

USA-based iBio Inc and Japan’s Kanematsu Chemicals, part of Kanematsu Corp have entered into a collaboration…

BiotechnologyBusiness FinanceiBio IncJapanKanematsuLicensingPharmacologyVaccines

Taiho Pharma and Sumitomo Dainippon both invest in Remiges BioPharma Fund

25-07-2014

Japanese oncology-focussed drugmaker Taiho Pharmaceutical has said that it will be investing $30 million…

BiotechnologyDainippon Sumitomo PharmaFinancialJapanOncologyRemiges BioPharma FundTaiho Pharmaceutical

Gilead submits for approval of hepatitis C drug Sovaldi in Japan

Gilead submits for approval of hepatitis C drug Sovaldi in Japan

27-06-2014

US biotech firm Gilead Sciences revealed this morning it has submitted a New Drug Application to Japan's…

Anti-viralsBiotechnologyGilead SciencesJapanRegulationSovaldi

Gilead’s ledipasvir/sofosbuvir achieved 100% SVR12 among chronic hepatitis C patients in Japan

Gilead’s ledipasvir/sofosbuvir achieved 100% SVR12 among chronic hepatitis C patients in Japan

16-06-2014

US anti-virals major Gilead Sciences has released strong top-line results from a Phase III clinical trial…

Anti-viralsBiotechnologyGilead SciencesJapanledipasvirRegulationResearchsofosbuvirSovaldi

Eisai's R&D unit Kan Research Institute starts full-scale operation at new facility

27-05-2014

Japanese drug major Eisai Co says that its R&D subsidiary KAN Research Institute held a dedication ceremony…

BiotechnologyEisaiImmunologicalsJapanKan Research InstituteNeurologicalOncologyResearch

Lupin inks strategic biosimilars joint venture agreement with Yoshindo

23-04-2014

Indian drugmaker Lupin has entered into a strategic joint venture agreement with Japanese pharma company,…

BiosimilarsBiotechnologyEnbrelInflammatory diseasesJapanLicensingLupinTakeda PharmaceuticalYoshindo

China set to overtake USA bioscience market

26-02-2014

Bioscience research in China is set to overtake the USA within the next five to ten years, data from…

Asia-PacificBiotechnologyChinaFinancialJapanResearchUSA

Parexel

Parexel

Back to top